|drug1195||Enoxaparin 40 Mg/0.4 mL Injectable Solution Wiki||0.71|
|D014777||Virus Diseases NIH||0.10|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
This QI project seeks to evaluate the relative test sample acquisition throughput, personal protective equipment utilization, and relative operational costs of provider-administered COVID-19 (SARS-CoV-2) nasal samples with and with the use of HEPA-filtered, positive pressure isolation booths.
Description: Samples acquired per hour using the Hexapod booth will be assessed as an average over a minimum of 12 weeks of testing compared to baseline throughput before April 16th.Measure: Change in Testing Throughput After Hexapod Implementation Time: Up to 22 weeks
Description: Gowns utilized per test will be assessed as an average over a minimum of 12 weeks of testing compared to baseline throughput before April 16th.Measure: Change in Isolation Gowns Utilized After Hexapod Utilization Time: Up to 22 weeks
Description: The difference in costs of collecting test samples before and after hexapod utilization will be calculated.Measure: Change in Cost per Test After Hexapod Implementation Time: Up to 22 weeks
Description: The retail cost of the Hexapod booth will be divided by the average daily cost differential for testing observed and at maximum volume.Measure: Return on Investment Time: Up to 22 weeks
Description: The difference in median shift salaries before and after Hexapod implementation will be calculated.Measure: Change in Testing Personnel Cost Per Test Time: Up to 22 weeks
Description: Outcome 2 will be utilized to calculate the range of the change in cost of isolation gowns utilized compared to baseline usage for samples acquired before April 16th utilizing actual and quoted costs of gowns to Materials Management at MGH.Measure: Change in Cost of Isolation Gowns Utilized Time: Up to 22 weeks
Description: The Materials Management costs of durable gloves, sleeves, and filters will be be calculated from the manufacturer's recommended monthly replacements of each per booth.Measure: Cost of Additional Consumable Supplies Utilized Time: Up to 22 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports